Drugs / LAD603
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06200597 | Dec 2023 → May 2025 | — | Almirall, S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07311564 | Dec 2025 → Jun 2027 expected | alopecia areata | Almirall, S.A. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAD603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07311564 ↗ |
| Route | Subcutaneous | “LAD603 SC injection.” NCT06200597 ↗ |